EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Evaluating treatment response thresholds for cost-effective treatment in metabolic dysfunction-associated steatotic liver disease

Eileen L Yoon, Jeong-Yeon Cho, Huiyul Park, Mimi Kim, Ji-Hyeon Park, Hye-Lin Kim, Dae Won Jun

Clinical and Molecular Hepatology · 01.01.2026 · 32 (1) · 276-288

DOI: 10.3350/cmh.2025.0796 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Molecular Hepatology, erschienen am 01.01.2026. Verfasst von Eileen L Yoon und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Hanyang University Hospital, Hanyang University College of Medicine, Seoul, Korea. Hauptthemen laut MEDLINE: Cost-Benefit Analysis, Fatty Liver. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Hanyang University, KIST Institutional Program, Patient-Centered Clinical Research Coordinating Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Aims: The first metabolic dysfunction-associated steatotic liver disease (MASLD) drug was approved with an unsatisfactorily small effect size. This study aimed to determine key factors impacting the cost-effectiveness of a new hypothetical MASLD drug as well as its treatment efficacy.

Methods

A Markov model reflecting the natural history of MASLD was developed, incorporating fibrosis progression, cardiovascular disease risk, and mortality. Treatment effect of drug X (with $20,000 of annual cost) was assumed to achieve a ≥1 stage fibrosis regression, with a 25% gap of effect size in regression rate over non-treatment in the first year. The incremental cost-effectiveness ratio (ICER) over a 20-year horizon was estimated. And sensitivity analyses were conducted to explore uncertainty and identify influential factors.

Results

In the base case analysis, drug X provided an incremental gain of 1.32 quality-adjusted life years (QALYs) and 1.20 life years compared to the non-treatment, with an ICER of $68,010/QALY–below the $100,000/QALY willingnessto- pay threshold, indicating that drug X treatment is cost-effective. Two-way sensitivity analysis further highlighted that the drug should achieve at least a 15% initial regression gap and maintain a minimum 3% sustained durability gap to remain cost-effective. In addition baseline fibrosis stage distribution also acted as an influencing factor.

Conclusions

Long-term sustained durability of the hypothetical drug, patient distribution based on baseline fibrosis stage, as well as initial treatment response rate are key factors that influence the cost-effectiveness of new MASLD drugs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cost-Benefit AnalysisFatty LiverHumansQuality-Adjusted Life YearsMarkov ChainsTreatment OutcomeLiver CirrhosisDisease Progression

Stichwörter der Autor:innen

Cost-effectiveness analysisDrug TherapyLiver cirrhosisMASLDMetabolic dysfunction-associated steatotic liver disease

Autor:innen und Institutionen

  • Department of Internal Medicine, Hanyang University Hospital, Hanyang University College of Medicine, Seoul, Korea.
  • Hanyang Institute of Bioscience and Biotechnology, Hanyang University, Seoul, Korea.
  • Department of Pharmacotherapy, University of Utah College of Pharmacy, Salt Lake City, UT, USA.
  • Department of Family Medicine, Myoungji Hospital, Hanyang University College of Medicine, Goyang, Korea.
  • Department of Radiology, Hanyang University College of Medicine, Seoul, Korea.
  • Department of Pharmacy, Sahmyook University College of Pharmacy, Seoul, Korea.

Förderung

  • Hanyang University
  • KIST Institutional Program
  • Patient-Centered Clinical Research Coordinating Center
  • Ministry of Health and Welfare
  • Seoul RISE Center
  • Ministry of Education
  • Seoul Metropolitan Government

Zitieren

APA

Yoon, E. L., Cho, J. Y., Park, H., Kim, M., Park, J. H., Kim, H. L., & Jun, D. W. (2026). Evaluating treatment response thresholds for cost-effective treatment in metabolic dysfunction-associated steatotic liver disease. Clinical and Molecular Hepatology, 32(1), 276-288. https://doi.org/10.3350/cmh.2025.0796

Vancouver

Yoon EL, Cho JY, Park H, Kim M, Park JH, Kim HL, et al. Evaluating treatment response thresholds for cost-effective treatment in metabolic dysfunction-associated steatotic liver disease. Clinical and Molecular Hepatology. 2026;32(1):276-288. doi:10.3350/cmh.2025.0796

BibTeX
@article{Yoon2026,
  author = {Yoon, Eileen L and Cho, Jeong-Yeon and Park, Huiyul and Kim, Mimi and Park, Ji-Hyeon and Kim, Hye-Lin and Jun, Dae Won},
  title = {Evaluating treatment response thresholds for cost-effective treatment in metabolic dysfunction-associated steatotic liver disease},
  journal = {Clinical and Molecular Hepatology},
  year = {2026},
  volume = {32},
  number = {1},
  pages = {276--288},
  doi = {10.3350/cmh.2025.0796}
}
Kostenlos starten →